Phosphagenics gets ethics nod for pain patch trial
08 April, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) has received ethics approval for a clinical trial of the redesigned version of pain patch TPM-oxycodone.
Alchemia granted oncology patent extension
05 April, 2013The US patent office has granted Alchemia (ASX:ACL) an extension for a key patent covering its HyACT oncology platform through to 2025.
Alchemia anticoagulant launches in India
04 April, 2013 by Dylan Bushell-EmblingAlchemia’s (ASX:ACL) marketing partner, Dr Reddy’s, has launched generic fondaparinux in India, marking its debut in a market outside of the US.
2013 Medical Device Commercialisation Seminar Series starts today
04 April, 2013The 2013 Medical Device Commercialisation Seminar Series explores what it takes to be one of the medical device success stories, helping today’s inventors fast-track to commercialisation.
$100 million allocated for new tranche of investment fund
04 April, 2013As part of the federal government’s recently announced industry and innovation plan ‘A Plan for Australian Jobs’, in which it announced a new $350 million round of the Innovation Investment Fund (IIF), $100 million has now been allocated.
Novogen’s CS-6 cytotoxic to resistant cancer cells
04 April, 2013 by Dylan Bushell-EmblingNovogen (ASX:NRT) shares surged on Wednesday after the company revealed lab results showing that its CS-6 candidate was highly cytotoxic to nigh-invulnerable ovarian cancer stem cell lines.
Phosphagenics in talks for TPM-diclofenac deal
03 April, 2013 by Dylan Bushell-EmblingPhosphagenics (ASX:POH) and Japan’s Nippon Zoki have progressed to the negotiation stage in their tie-up to produce an anti-inflammation product for the US market.
Funding boost for start-ups
03 April, 2013At least $200 million will be invested in start-up companies under the latest tranche of the federal government’s Innovation Investment Fund.
Calzada completes treatment in NovoSorb trial
02 April, 2013 by Dylan Bushell-EmblingCalzada’s (ASX:CZD) PolyNovo unit has wrapped up a human trial involving using NovoSorb in vacuum-assisted closure of pressure sores.
Bioniche resumes control of bladder cancer drug
02 April, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) is back in control of commercialisation activities for bladder cancer treatment Urocidin after wrapping up its partnership with Endo Pharmaceuticals.
pSivida’s treatment for chronic diabetic macular edema awaits FDA approval
02 April, 2013pSivida licensee Alimera Sciences has made a resubmission to the US Food and Drug Administration for approval of Iluvien for chronic diabetic macular edema.
Bioniche secures grant for E. coli vaccine project
02 April, 2013 by Dylan Bushell-EmblingBioniche (ASX:BNC) will receive up to C$500,000 in funding from Canada’s NRC to support the development of a new generation of its E. coli O157 cattle vaccine.
TGA proposes changes to pre-market assessment for medical devices
02 April, 2013AusBiotech’s March industry submission addresses the Therapeutic Goods Administration’s (TGA) proposed changes to the pre-market assessment requirements for medical devices.
Partnership to further develop anticancer formulation
28 March, 2013The University of Wollongong (UOW) has licensed the commercialisation rights to a novel drug formulation for the treatment of metastatic colorectal cancer (mCRC) to a local biotech company - FivePhusion.
Bioniche welcomes Canadian investments in R&D
28 March, 2013Bioniche (ASX:BNO) has lauded decisions by the Canadian government to provide more funding for programs which support R&D and commercialisation efforts by the nation’s companies.
